You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《新股》銀諾醫藥(02591.HK)今起招股 一手入場費3,773.68元
銀諾醫藥-B(02591.HK)公布招股詳情,擬全球發售3,655.64萬股H股,香港公開發售佔約一成,國際發售佔約九成。每股招股價18.68元。每手200股計,一手入場費3,773.68元。該股今日(7日)起招股,下周二(12日)中午截止,預期將於下周五(15日)掛牌。聯席保薦人為中信証券及中金。 公司上市引入駿昇、Ginkgo Fund、邁富時(02556.HK)、鄧海峰及黎慧鳳為基石投資者,認購公司1,000萬美元(約7,850萬港元)股份。 此外,公司上市料淨籌約6.1億元,當中約90%擬用於正在進行及計劃中的臨床試驗以及核心產品依蘇帕格魯(月太)α的計劃商業化上市;約10%擬用於營運資金及一般公司用途。 銀諾醫藥為亞洲第一家及全球第三家商業化原研人源長效胰高血糖素樣(月太)-1 (GLP-1)受體激動劑的公司,已在中國將用於治療2型糖尿病(T2D)的核心產品依蘇帕格魯(月太)α(商品名:怡諾輕)商業化。公司致力於開發糖尿病和其他代謝性疾病的療法。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account